Prof. Hong Qiu 邱红
Chief Physician, Professor
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive treatment of gastrointestinal tumors including gastric, colorectal, and esophageal cancer. Expertise in cancer pain management, symptom control, chemotherapy, radiotherapy, and targeted therapy.
Dr. Qiu is a Professor and Chief Physician with a medical doctorate from Huazhong University of Science and Technology (2001). With nearly 20 years of clinical experience, Dr. Qiu specializes in the precise radiotherapy and comprehensive treatment of digestive and urinary system tumors. Dr. Qiu studied in Japan and has published over 60 papers. Dr. Qiu leads national research projects and has received provincial and municipal science and technology progress awards.
Professional roles
- Vice Chair, Targeted Therapy Professional Youth Committee, China Anti-Cancer Association
- Vice Chair, Cancer Supportive Care Youth Committee, China Anti-Cancer Association
- Vice Chair, Gastric Cancer Professional Committee, Beijing Cancer Prevention and Treatment Society
- Standing Committee Member, Clinical Oncology Professional Committee, Chinese Women Doctors Association
Name order: in Chinese the family name comes first (Qiu Hong). Papers usually list the name as Hong Qiu or Qiu H.
Selected publications
79 papers on PubMed matched by name and affiliation; 23 as first or senior author since 2016. Most recent first- or senior-author papers:
- Biochim Biophys Acta Mol Basis Dis, 2027 (senior author): Detachment-induced ETS1 drives anoikis resistance and metastasis through STX3-mediated PTEN ubiquitination in gastric cancer. PubMed 42735835
- Oncologist, 2025 (senior author): Trophoblast cell-surface antigen 2 expression in digestive neoplasms: a promising target for antibody-drug conjugates. PubMed 41100061
- Insights Imaging, 2025 (senior author): Computed tomography radiomics to predict microsatellite instability status and immunotherapy response in gastric cancer. PubMed 40813941
- Oncologist, 2025 (senior author): Multi-center phase II study of nab-paclitaxel plus camrelizumab versus nab-paclitaxel alone as second-line treatment for advanced gastric cancer. PubMed 40554667
- Clin Transl Oncol, 2025 (senior author): Cancer cell-extrinsic STING shapes immune-active microenvironment and predicts clinical outcome in gastric cancer. PubMed 39412634
- Oncologist, 2025 (senior author): Prophylactic antibiotic use is associated with better clinical outcomes in gastric cancer patients receiving immunotherapy. PubMed 40036772
- PeerJ, 2023 (senior author): A contrast-enhanced CT-based whole-spleen radiomics signature for early prediction of oxaliplatin-related thrombocytopenia in patients with gastrointestinal malignancies: a retrospective study. PubMed 37849829
- Front Immunol, 2023 (senior author): Identification of molecular pattern and prognostic risk model based on ligand-receptor pairs in liver cancer. PubMed 37818360
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion